SPH7050 / Shanghai Pharma - LARVOL DELTA

Discovery of a gut-restricted LANCL2 agonist for the treatment of inflammatory bowel disease. (PubMed, Eur J Med Chem) - "In the 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced mouse colitis model, SPH7050 dose-dependently reduced disease activity index and colonic inflammation, outperforming BT-11 at equal doses and matching mesalazine (100 mg/kg, QD) in efficacy with an identical total daily dose but a divided dosing regimen (50 mg/kg, BID). These data support SPH7050 as a viable next-generation LANCL2 agonist and illustrate how conformational rigidification can reshape binding geometry in a gut-restricted therapeutic context."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • LANCL2